Norrie Disease (Pseudoglioma) (NDP) Peptide
NDP
Reactivity: Mammalian
Host: Synthetic
BP, IHC, WB
-
- Target See all Norrie Disease (Pseudoglioma) (NDP) products
- Norrie Disease (Pseudoglioma) (NDP)
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Sequence
- DPRRCMRHHY VDSISHPLYK CSSKMVLLAR CEGHCSQASR SEPLVSFSTV
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of NDP antibody,
Alternative Names: NDP control peptide, NDP antibody Blocking Peptide, Anti-NDP Blocking Peptide, Norrie Disease Blocking Peptide, Pseudoglioma Blocking Peptide, EVR2 Blocking Peptide, FEVR Blocking Peptide, ND Blocking Peptide - Purification
- Rabbit Anti-p44/42 MAP Kinase (Ab-202) Polyclonal Antibody is affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen.
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- Norrie Disease (Pseudoglioma) (NDP)
- Background
- NDP activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. NDP plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. NDP acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1).
- Molecular Weight
- 15 kDa
-
You are here:
